Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia by Khanim, Farhat L. et al.
Combined Bezafibrate and Medroxyprogesterone
Acetate: Potential Novel Therapy for Acute Myeloid
Leukaemia
Farhat L. Khanim
1, Rachel E. Hayden
1, Jane Birtwistle
1, Alessia Lodi
2, Stefano Tiziani
2, Nicholas J.
Davies
1, Jon P. Ride
1, Mark R. Viant
1, Ulrich L. Gunther
2, Joanne C. Mountford
3, Heinrich Schrewe
4,5,
Richard M. Green
1, Jim A. Murray
6, Mark T. Drayson
7., Chris M. Bunce
1.*
1School of Biosciences, University of Birmingham, Birmingham, United Kingdom, 2Henry Wellcome Building for Biomolecular NMR Spectroscopy, CRUK Institute for
Cancer Studies, University of Birmingham, Birmingham, United Kingdom, 3Division of Cancer Sciences and Molecular Pathology, University of Glasgow, Glasgow, United
Kingdom, 4Department of Developmental Genetics, Max-Planck Institute for Molecular Genetics, Berlin, Germany, 5Institute of Medical Genetics, Charite ´-University
Medicine Berlin, Berlin, Germany, 6Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom, 7Division of Immunity and Infection,
University of Birmingham, Birmingham, United Kingdom
Abstract
Background: The majority of acute myeloid leukaemia (AML) patients are over sixty years of age. With current treatment
regimens, survival rates amongst these, and also those younger patients who relapse, remain dismal and novel therapies are
urgently required. In particular, therapies that have anti-leukaemic activity but that, unlike conventional chemotherapy, do
not impair normal haemopoiesis.
Principal Findings: Here we demonstrate the potent anti-leukaemic activity of the combination of the lipid-regulating drug
bezafibrate (BEZ) and the sex hormone medroxyprogesterone acetate (MPA) against AML cell lines and primary AML cells.
The combined activity of BEZ and MPA (B/M) converged upon the increased synthesis and reduced metabolism of
prostaglandin D2 (PGD2) resulting in elevated levels of the downstream highly bioactive, anti-neoplastic prostaglandin 15-
deoxy D
12,14 PGJ2 (15d-PGJ2). BEZ increased PGD2 synthesis via the generation of reactive oxygen species (ROS) and
activation of the lipid peroxidation pathway. MPA directed prostaglandin synthesis towards 15d-PGJ2 by inhibiting the PGD2
11b -ketoreductase activity of the aldo-keto reductase AKR1C3, which metabolises PGD2 to 9a11b-PGF2a. B/M treatment
resulted in growth arrest, apoptosis and cell differentiation in both AML cell lines and primary AML cells and these actions
were recapitulated by treatment with 15d-PGJ2. Importantly, the actions of B/M had little effect on the survival of normal
adult myeloid progenitors.
Significance: Collectively our data demonstrate that B/M treatment of AML cells elevated ROS and delivered the anti-
neoplastic actions of 15d-PGJ2. These observations provide the mechanistic rationale for the redeployment of B/M in elderly
and relapsed AML.
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Introduction
Acute myeloid leukaemia (AML) is a devastating cancer
characterised by the uncontrolled proliferation, abnormal survival
and arrested maturation of leukaemic cells within the bone
marrow. The rapid expansion of the leukaemic clone reduces
haemopoiesis with loss of normal functioning neutrophils,
platelets, and erythrocytes. If untreated, most patients die from
infection, bleeding and/or anaemia within weeks of diagnosis.
Current best treatments utilise anthracyclines e.g. daunorubicin
or idarubicin, alongside the pyrimidine and purine analogue
cytarabine with or without 6-thioguanine [1,2]. These drugs non-
selectively inhibit DNA and RNA synthesis and consequently their
anti-leukaemic activity is associated with high levels of systemic
toxicity, including further reduction of haemopoiesis. Although the
current therapies of choice, these agents fail to cure more than two
thirds of those patients deemed able to tolerate the therapy [2,3,4].
The problem is further exacerbated by the molecular heteroge-
neity underlying the disease as well as its distribution within the
population. AML incidence increases with age and .75% of
patients are older than 60 years of age at diagnosis. These older
patients have a much reduced capacity to tolerate high dose
chemotherapy and their leukaemia’s are associated with higher
frequencies of unfavourable prognostic factors [5]. As a result,
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improvement having been made over the last 20 years [2,3,4,6,7].
This lack of progress coupled with the frail nature of these patients
presents them and their clinicians with limited therapeutic options.
The majority of elderly patients receive supportive care alone or
with non-intensive therapy [4,8]. A review of 36 AML studies
involving a total of 12,370 patients (median age 70 yrs) found that
the median overall survival for patients receiving supportive care
alone was only 7.5 weeks and for those receiving supportive care
with non-intensive therapy only 12 weeks [5].
Knowledge of the molecular pathogenesis of AML and other
leukaemia’s has led to attempts to develop specific targeted
agents and a number of these are now in clinical trial [2,4,9].
However, with the notable exception of all-trans retinoic acid
(ATRA) in a subset of AML known as acute promyelocytic
leukaemia (APL)[10], and imatinib mesylate (Glivec) and its
derivatives in chronic myeloid leukaemia (CML)[11], few of
these therapies have as yet had a large scale impact. This has
lead to trials using combinations of targeted therapies [12].
However, the problem of developing targeted therapies for
AML is complicated by the inherent heterogeneity and genetic
complexity of the disease. Thus whilst attempts at new drug
discovery remain important, their low success rates, long time
scales and high costs impose serious limitations on progress for
improving the outlook in this disease.
‘Drug redeployment’ provides an alternative treatment
strategy that is gaining momentum across a broad spectrum of
diseases [13,14]. This approach tests the potential of established
drugs in new disease settings. We and others have previously
demonstrated the individual in vitro anti-proliferative and pro-
differentiative actions of the sex steroid medroxyprogesterone
acetate (MPA) and lipid regulating fibrate drugs against AML
cell lines [15,16,17,18], Burkitts lymphoma (BL) cells [19] and
chronic lymphocytic leukaemia (CLL) cells [20]. Here we
demonstrate improved combinatorial activity of bezafibrate
(BEZ) and MPA(B/M) against AML cell lines andprimaryAML
cells. We demonstrate that the activity of the drugs when
combined remains selective against AML cells over normal
myeloid blasts. Furthermore we demonstrate that the antitumor
activity of B/M against AML cell differs from the activity of the
same drugs against CLL cells in that it converges on the
increased synthesis and decreased metabolism of prostaglandin
D2 (PGD2)a n di t sp o t e n t l ya n t in e o p l a s t i cd e r i v a t i v e
15deoxyD
12, 14 prostaglandin J2 (15d-PGJ2).Several studies have
identified potent activities of 15d-PGJ2 against diverse cancers
[21,22,23,24,25,26,27,28,29]. The cyclopentenone configura-
tion of this prostaglandin renders it highly reactive facilitating
non-enzymatic covalent bonding to thiol residues in multiple
biological substrates [30,31,32,33,34,35,36,37,38]. The result is
modulation of the activity and/or levels of multiple cellular
targets, the spectrum of which will be cell context specific but
which most likely explain the broad anti tumour activity of 15d-
PGJ2. Given its bioactive nature, administration of 15d-PGJ2 is
likely to be associated with high toxicity and low bioavailability
due to conjugation of 15d-PGJ2 to extracellular targets,
including serum proteins [39]. An improved strategy is therefore
to promote the accumulation of endogenously formed 15d-PGJ2
within target cells. Since 15d-PGJ2 arises non-enzymatically
from PGD2 [40,41] the elevated synthesis of this prostanoid is in
turn dependent on the elevation of PGD2. We demonstrate here
that in the case of AML, elevation of PGD2 and 15d-PGJ2
with associated anti-leukaemic activity can be achieved with
drugs that are available, relatively cheap and familiar in the
clinical setting.
Results
The Anti-Leukaemic Actions of BEZ and MPA against AML
Cell Lines Are Most Potent When Combined
Figure 1A shows the dose dependent killing of KG1a cells by
MPA and BEZ and illustrates the greater individual potency of
BEZ. After 10 days treatment with 0.5 mM BEZ cell viability
had been reduced to 20% of controls whereas 5 mMM P Ah a d
reduced cell viability to just 60% of controls. In BEZ and MPA
cross titration experiments, potentiation of killing of KG1a
cells was clearly evident with near total loss of viability with
0.5 mM BEZ and 5 mM MPA after 10 days (Figure 1B).
Similar results were also observed in HL60 and K562 cells
(data not shown) and are consistent with our previous studies in
Burkitt’s lymphoma cells [19]. Consequently, all subsequent
experiments were performed with 0.5 mM BEZ and 5 mM
MPA both when alone and in combination (B/M). The anti-
proliferative effects of BEZ and MPA on a panel of cell lines
representing diverse forms of AML including U937, NB4
(PML:RARa
+ve APL), HL-60, K562 (BCR:ABL
+ve AML blast
crisis of chronic myeloid leukaemia) and KG1a cells are shown
in Figure 1C and Figure S1. As in KG1a cells, BEZ was the
more potent antiproliferative individual agent in U937, NB4
and HL60 cells although neither agent alone was particularly
effective against K562 cells. However, B/M treatment was the
most potent (p,0.01) at reducing cell number across all the
cell lines examined.
BEZ and MPA Variably Induces Differentiation and
Apoptosis in Myeloid Cell Lines
The myeloid cell surface antigen CD11b was used in flow
cytometry to assess differentiation of U937, NB4, HL60 and
KG1a cells. Erythroid differentiation of K562 cells was measured
by glycophorin A (Gly A) expression. Consistent with our earlier
findings in HL60 cells, MPA alone caused little or no
differentiation in any of the cell lines (Figure 2A & Figure S2A)
whereas BEZ induced differentiation of U937, NB4 and HL60
cells to varying degrees. Combined B/M treatment induced
markedly increased CD11b expression in HL60 cells compared to
the individual agents. The combinatorial action of B/M upon
HL60 differentiation was confirmed by the reciprocal loss of the
more primitive cell marker CD71 (Figure 2B). B/M combined
treatment also induced differentiation of U937 and NB4 cells but
in these cells there was no increase in B/M over BEZ alone
(Figure 2A & Figure S2A). In marked contrast MPA, BEZ and B/
M failed to induce either the erythroid or myeloid differentiation
of K562 or KG1a cells respectively. This was confirmed by
analyses of cell morphology. As shown in Figure 2C, B/M treated
NB4 and HL60 cultures clearly contained maturing neutrophils
whereas maturing cells were not evident in B/M treated KG1a
cultures.
Cell cycle analyses at day 7 identified a marked G1 cell cycle
arrest in those cell lines that displayed differentiation in response to
B/M (data not shown). In K562, KG1a and U937 but not HL-60
and NB4 cells, cell cycle analyses further identified the
accumulation of a sub-G1 fraction, indicative of post apoptotic
cells (Figure 2D & Figure S2B). These data indicated that the cell
responses to B/M treatment were varied, ranging from strong cell
cycle arrest and differentiation to apoptosis. A more detailed
comparison of KG1a and HL60 cells confirmed induction of
annexin-V labelling (Figure 2E) together with uptake of propidium
iodide (PI), consistent with apoptosis in KG1a cells but not in
HL60 cells (Figure 2E and 2F).
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Recapitulated in Primary AML Cells but Not Normal
CD34
+ve Cells
Primary AML cells also demonstrated in vitro sensitivity to BEZ,
MPA and B/M (Figure 3A). At day 8, control cultures originally
plated at 1610
6 cells/ml contained 1.160.13610
6 cells/ml. In
contrast B/M treated cultures contained 0.5260.11610
6 cells/ml
(p,0001). Morphological examination of primary AML cultures
(not shown) and cytospins (Figure 3B) prepared from B/M treated
AML cells indicated that B/M induced loss of cells was
most frequently mediated by cell killing rather than overt
differentiation.
In marked contrast, treatment with BEZ, MPA or B/M had
little effect on normal myeloid progenitors (CD34+ve cells).
Unsorted mobilised mononuclear cells which are enriched with
CD34+ve myeloid progenitors were treated for 8 days. No changes
in cell number were recorded in response to either drug alone and
only a small decrease was observed following B/M treatment.
Despite this decrease, the proportion of viable CD34+ve cells
increased, indicating no significant loss of these cells (Figure 3C).
Similarly, treatment of purified mobilised normal donor CD34+ve
cells with BEZ, MPA and B/M did not result in apoptosis or frank
differentiation. After 8 days, B/M treated cultures contained 89%
of the number of viable cells in untreated cultures. Furthermore,
although a slight diminution of CD34 fluorescence intensity was
observed, overt differentiation as measured by the maturation
marker CD11b was not induced (Figure 3D).
MPA Targets AKR1C3 in AML Cells
We and others have shown AML cells to express the aldo-keto
reductase AKR1C3 [42,43,44] and our rationale for selecting
MPA for redeployment as a potential antileukaemic drug is as an
inhibitor of this enzyme [28]. However, although MPA had been
shown to inhibit other aldo-keto reductases [45], it had not been
directly demonstrated as an inhibitor of AKR1C3. Like other
members of the AKR1C subfamily of aldo-keto reductases,
AKR1C3 displays substrate promiscuity [46] but amongst the
human sub-family possesses unique PGD2-11-ketoreductase activ-
ity generating 11b-PGF2a from PGD2. Our previous studies have
shown that this activity is prominent in AML cells but not
detectable in CLL cells [44,20]. MPA inhibited both the cellular
AKR1C3 activity in KG1a myeloid cells, as measured by the
decreased conversion of
3H-PGD2 to
3H-11b-PGF2a (Figure 4A),
and the in vitro activity of recombinant-AKR1C3 protein
(IC50=1.1 mM; Figure 4B). In dose response experiments
performed in KG1a cells, the inhibition of AKR1C3 mediated
PGD2 conversion to 11b-PGF2a mirrored the dose response of
reduced cell viability (Figure 4C). Together these data and those
from our previous study that identify AKR1C3 as having PGD2-
11-keto reductase activity in AML cell lines [44] support our
model of the action of MPA against AML cells.
The Anti-Leukaemic Activities of BEZ Are Associated with
ROS Generation
The original rationale made by ourselves and others for the
redeployment of fibrates as anti-AML agents, was based on
t h e i ra c t i v i t ya sl i g a n d sf o rt h en u c l e a rr e c e p t o rP P A R a.
However, the required BEZ concentrations observed here
suggest an alternative mechanism. BEZ has previously been
shown to induce oxidative stress in cells [47,48]. In keeping
with this, BEZ treatment of K562 and KG1a cells induced a
rapid (within 2 hours, data not shown) and sustained
generation of reactive oxygen species (ROS) that was BEZ
Figure 1. Dose dependent killing by BEZ, MPA and B/M of
myeloid cell lines. Cell viability as % of solvent treated controls was
determined in KG1a cells by Cell-Titre Blue assay following 10 days
treatment with (A) increasing doses of MPA or BEZ alone, or (B) cross-
titrations of BEZ (mM) and MPA (mM). Data shown is mean of N=3
experiments (C) 5 different myeloid cell lines were treated with either
solvent control, 0.5 mM BEZ, 5 mM MPA or the combination (B/M) for 7
days. Cell viability was calculated for treatments relative to solvent
treated controls after readings had been adjusted for feeding regimens
over the 7 days of treatment. Mean6sem is shown for 5 cell lines from a
minimum of N=3 experiments. Individual datapoints are shown in
Figure S1. Statistics * p,0.01.
doi:10.1371/journal.pone.0008147.g001
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tion of ROS was observed in all AML cell lines when treated
with 0.5 mM BEZ (Figure 5C). Finally, using the example
of KG1a cells, we observed that cell killing by BEZ tightly
correlated with the percentage of ROS positive cells
(Figure 5D).
The Actions of BEZ and MPA on AML Cells Converge on
the Accumulation of PGD2 and Its Downstream Reactive
Product 15d-PGJ2
PGD2 is synthesised from arachidonic acid by both a
cyclooxygenase (COX)-dependent pathway [49] and COX-
independent, an oxidative stress-dependent, lipid peroxidation-
isoprostane pathway [50] (Figure S3). Given that the lipid
peroxidation-dependent isoprostane pathway has been shown to
be elevated in periods of oxidative stress [51], we postulated that
BEZ-induced oxidative stress would result in lipid peroxidation.
Consistent with this, 0.5 mM BEZ treatment of AML cell lines
labelled with the naturally fluorescent lipid cis-parinaric acid was
associated with a significant decrease in fluorescence, indicative of
increased lipid peroxidation (Figure 6A). We therefore reasoned
that the effects of BEZ and MPA may converge on the elevation of
cellular PGD2 via increased lipid peroxidation-mediated synthesis
and decreased metabolism by AKR1C3. We also reasoned that as
a consequence of increased PGD2 levels, the levels of its potently
anti-neoplastic dehydration product 15d-PGJ2 would also be
elevated. Indeed, treatment with MPA or BEZ alone and B/M
resulted in increased levels of both PGD2 and 15d-PGJ2 in HL60
and KG1a cells (Figure 6B & C). MPA induced 3.360.9 fold and
3.860.9 fold increases in PGD2 in HL60 and KG1a, respectively
as compared to solvent treated control cells (Figure 6B). As may be
expected of an inducer of lipid peroxidation and therefore
increased isoprostane pathway activity, the effects of BEZ were
greater than MPA with 13.761.6 and 28.469.9 fold increases in
PGD2 in HL60 and KG1a, respectively (Figure 6B). B/M gave the
most marked elevation especially in HL-60 cells with a 43.469.9
fold increase, whereas KG1a had a 35.1612.2 fold increase. 15d-
PGJ2 levels followed a similar trend in both cell lines (Figure 6C).
It has been demonstrated that 15d-PGJ2 itself can potently
induce ROS [21]. Consistent with this, treatment of AML cell
lines and primary AML cells with 15d
2PGJ2 also resulted in the
induction of ROS levels similar to those seen in response to B/M
(Figure S4). Furthermore, treatment of HL60, K562 and KG1a
cells with 15d-PGJ2 recapitulated the antiproliferative actions of
B/M (Figure 6E) and the enhanced differentiation of HL-60 cells
but not of K562 or KG1a cells (Figure 6F).
Figure 2. Cellular consequences of MPA and BEZ treatment. (A) Differentiation was measured by flow-cytometry using the myeloid
differentiation antigen CD11b for HL60, NB4, U937, KG1a cells and the erythroid antigen Glycophorin-A for differentiation of K562. Mean data6sem
from a minimum of N=3 experiments are shown. All datapoints are shown in Figure S2A. (B) Representative dotplots for HL60 cells following 7 days
treatment stained both with CD11b and the proliferation marker CD71. Pale blue shows non-differentiated cells (CD71+, CD11b2), dark blue cells
that have lost CD71 (CD712, CD11b2), and pink identifies differentiated neutrophils (CD712, CD11b+). (C) Cell morphology was analysed by Jenner-
Giemsa staining of cytospin preparations of cells treated for 7 days. Apoptotic cells are highlighted by a star and differentiating neutrophils by an
arrow. (D) % Sub-G1 events were measured by cell cycle analysis of propidium iodide stained cells following 7 days treatment. Mean data6sem for 5
cell lines from a minimum of N=3 experiments are shown. All datapoints are shown in Figure S2B. (E) HL60 and KG1a cells were treated with either
solvent CONT or B/M for 48 hours. Apoptosis was assessed by incubation with annexin-V and propidium iodide followed by flow cytometry.
Individual datapoints from a minimum of N=4 are shown with a black bar indicating the mean. (F) Representative dotplots of annexin V and
propidium iodide stained HL60 and KG1a cells following treatment with either solvent CONT or B/M for 48 hours. Statistics *p,0.01.
doi:10.1371/journal.pone.0008147.g002
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15d-PGJ2
The above observations suggested that the activities of B/M
against AML cells may be largely mediated by the generation of
15d-PGJ2. Previous studies have identified multiple mechanisms
by which 15d-PGJ2 exerts its anti-neoplastic activity. The nature
and range of these actions suggests that the detailed effects of 15d-
PGJ2 against individual tumours may show cell context specificity.
We studied some of the previously reported activities of 15d-PGJ2
in AML cells following treatment with BEZ and MPA.
Glutathione depletion. The ratio and amounts of reduced
glutathione (GSH) and oxidised glutathione (GSSG) are important
in regulating the redox state of a cell. Under conditions of oxidative
stress, GSH/GSSG levels become depleted and imbalanced,
leading to cell differentiation or cell death. Importantly, 15d-PGJ2
concentrations that induce apoptosis and differentiation have been
associated with depletion of cellular GSH [21,52]. Furthermore,
15d-PGJ2 levels have been shown to be tightly regulated through
GSH-conjugation and subsequent cellular export [53,54,55]. We
therefore determined changes in GSH levels following treatment
with BEZ, MPA and B/M. Significant decreases in both GSH
(Figure 7A) and GSSG (Figures S5 & S6) levels were observed
following drug treatment. In the case of GSH reduction the B/M
effect was not greater than either drug alone whereas the greatest
reduction in GSSG was observed in response to B/M (Figure S6).
PPARc activation. Amongst the first biological activities
ascribed to 15d-PGJ2 was as an activating ligand for the nuclear
receptor PPARc [56,57]. Luciferase reporter assays in transiently
transfected HL60 cells identified PPARc-activation in response to
MPA, BEZ and B/M (Figure 7B). Although small, the observed
Figure 3. BEZ and MPA also kill primary AML cells but not normal myeloid progenitors. (A) Primary AML cells were treated for 5 days. Cell
numbers were determined by manual counts and are presented as number of cells610
6/ml at day 5. The plot shows summary data for 9 individual
AMLs and the mean identified by bars. (B) Cell morphology for 2 representative AML samples are shown as determined by Jenner-Giemsa staining of
cytospin slides. (C) Non-sorted mobilised peripheral blood cells were treated with solvent CONT or B/M. Histogram shows representative CD34
staining after 8 days treatment. (D) CD34+ve purified normal mobilised cells were treated with either solvent CONT or B/M for 8 days. The dotplots
shown are CD34 and CD11b expression following treatment.
doi:10.1371/journal.pone.0008147.g003
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15d-PGJ2 treatments.
IkB-accumulation. 15d-PGJ2 has been showntoregulate NF-
kB activityat multiple levels [30,31]. This includes regulationofIkB
(inhibitor of kB) protein levels by inhibiting the activity of the IKK
(IkB-kinase) complex that targets IkB for ubiquitin-mediated
protein degradation [30]. Inhibition of IkB-phosphorylation
results in its accumulation and consequent inhibition of NF-kB
transcriptional activity. Western blot analysis revealed IkB-
accumulation in MPA, BEZ and B/M treated HL60 cells
(Figure 7C & D, Figure S7). The pattern of IkB accumulation
mirrored that of 15d-PGJ2 accumulation with MPA having the least
or little effect, BEZ having a greater effect and the combination
being most effective. Similar accumulations were observed in U937
cells and in a sample of primary AML cells, (Figure 7D) however
KG1a and NB4 cells did not show an accumulation of IkB
(Figure 7C&D,FigureS7).Since15d-PGJ2 isknowntoregulate NF-
kB transcriptional activity at multiple levels we cannot rule out the
possibility that B/M may alter NF-kB in KG1a and NB4 cells by
mechanisms other than accumulation of IkB.
The Cellular Activities of BEZ and MPA Are Enhanced by
Physiological Levels of Vitamin A and Vitamin D3
When considering the translation of this study into a clinical
trial we wished to better understand how to exploit these effects.
Since we and others have previously shown that fibrates and MPA
each separately enhance ATRA and 1a,25(OH)2 vitamin D3 (D3)
induced HL-60 cell differentiation [15,17,58] we reasoned that
where the combined action of B/M results in differentiation this
may be reciprocally limited in the absence of ATRA and D3. In an
attempt to mimic physiological levels of ATRA and D3 that might
be expected in patients with adequate daily vitamin A and D
intake, we treated HL60 cells with B/M together with 1 nM
ATRA, 1 nM D3 and the combination (ATRA/D3). As in
Figure 4. MPA inhibits AKR1C3 PGD2 11b keto-reductase activity. (A)
3H-PGD2 turnover was determined by thin layer chromatography (TLC)
on KG1a cells treated with either solvent control or 5 mM MPA. Representative TLC traces are shown from a minimum of N=4 experiments.
Abbreviations; O=origin, F2a =11b-PGF2a,D 2=PGD2.( B) Inhibition of recombinant AKR1C3 protein activity by MPA. The plot shows percentage of
AKR1C3 activity in the presence of increasing concentrations of MPA relative to AKR1C3 in the absence of MPA. The data are means6s.d. from a
single experiment performed in triplicates. (C) Conversion of
3H-PGD2 to 9a-11b-PGF2a was determined by TLC in KG1a cells treated with MPA
titrations and compared to cell viability at day 10. Mean data6sem from a minimum of N=3 are shown.
doi:10.1371/journal.pone.0008147.g004
Targeting 15d-PGJ2 in AML
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cells, 1 nM ATRA+1n MD 3 (ATRA/D3) alone caused differen-
tiation in ,35% as measured by expression of the differentiation
marker CD11b at day 7 (Figure 8A). However, morphologically
relatively few cells had reached terminal neutrophil differentiation
(Figure 8B). Addition of ATRA or D3 individually to B/M
resulted in a significant increase in differentiated cells (Figure 8A).
However, the addition of B/M together with ATRA/D3 resulted
in ,90% of cells expressing increased CD11b and morphologi-
cally all cells had differentiated into polymorphonuclear neutro-
phils and/or undergone apoptosis (Figure 8A & B) demonstrating
strong complementary interactions between B/M and physiolog-
ical levels of ATRA and D3. Prolonged survival and differentiation
was rarely seen in primary AML cells however, when it did occur,
we also observed complimentarity between B/M and ATRA/D3.
This is illustrated in the primary AML (non-APL) sample shown in
Figure 8C. CD11b expression was detected in 4.5% of control cells
compared to 17.5% in ATRA/D3 treated cells. B/M alone
induced CD11b expression in 32%, which was further increased to
46% when cells were treated with B/M & ATRA/D3 (Figure 8C).
Interestingly, the addition of ATRA/D3 did not interfere with
induction of ROS by B/M indicating that these agents were
working by complementary actions (Figure 8D).
Discussion
Drug redeployment has already demonstrated great promise in
haemato-lymphoid malignancies including, thalidomide in mye-
loma [59] and valproic acid and arsenic trioxide in AML [60,61].
However, few studies have sought to redeploy combinations of old
drugs that deliver greater potency than either drug alone. We
demonstrate here that exploiting some understanding of the
mechanisms of drug actions against cancer cells allows the rational
testing of such potentially beneficial combinations.
The anti-neoplastic activities of 15d-PGJ2 have been described
in many reports [21–29], however few studies have sought
Figure 5. BEZ induction of ROS is concentration dependent and correlates with cell killing. BEZ induced reactive oxygen species (ROS)
were measured at 14 hours by staining with carboxy-H2DCFDA and analysis by flow cytometry. (A) Histogram shows representative results from HL60
cells. (B) ROS induction was measured in K562 and KG1a cells after 14 hrs treatment with different BEZ concentrations (mean6sem from N=4
experiments). (C) ROS induction with 0.5 mM BEZ for 5 myeloid cell lines is shown from a minimum of N=3 experiments for each cell line. Mean is
indicated by black bar. (D) % viable KG1a cells at day 10 compared to controls plotted against the % cells positive for ROS at increasing BEZ
concentrations. Statistics *p,0.01.
doi:10.1371/journal.pone.0008147.g005
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cells labelled with the naturally fluorescent lipid cis-parinaric acid. Data is presented as % fluorescence units (FU) compared to solvent control
cells for N=5 experiments for each cell line. Mean is indicated by black bar. (B&C ) Endogenous levels of (B)P G D 2 and (C) 15d-PGJ2 were
determined in HL60 and KG1a cells by ELISA following 2 hours treatment. P r o s t a g l a n d i nl e v e l sa r es h o w nr e l ative to untreated controls for a
minimum of 4 experiments. Mean is indicated by black bars. Statistics: * p,0.05. (D) ROS induction was determined by staining with DCFDA
and flow cytometry in HL60, KG1a and primary AML samples (n=3) after 48 hours treatment with CONT, B/M or 10 mM 15d-PGJ2. Data shown
are mean6sem. Individual datapoints are shown in Figure S4. (E&F ) HL60, K562 and KG1a cells were treated for 7 days with either solvent
control or 5 mM 15d-PGJ2. Data is shown from a minimum of N=3 experiments. Mean is indicated by black bar. (E) Cell viability was assessed
by Alamar blue and calculated as % of control cells. (F) Differentiation was assessed by CD11b staining of HL60 and KG1a and GlyA staining of
K562 cells followed by flow cytometry. Statistics: * p,0.01.
doi:10.1371/journal.pone.0008147.g006
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nilylproline derivative, Fuligocandin B, has been shown to induce
15d-PGJ2 production in treated cells the compound has yet to
undergo toxicity testing in humans [62]. Here, we demonstrate
that 15d-PGJ2 and its precursor, PGD2, can be elevated in AML
cells using already available drugs with good safety profiles. BEZ
treatment mediated sustained ROS generation with associated
lipid peroxidation, downstream synthesis of PGD2 and conse-
quently, generation of 15d-PGJ2. MPA, further elevated PGD2
and 15d-PGJ2 levels by inhibiting the metabolism of PGD2 by
AKR1C3 (Figure S8).
15d-PGJ2 is a cyclopentenone prostaglandin. These prostaglan-
dinshave unsaturated a,b ketonemoieties that allow non-enzymatic
covalent modification of cellular targets [63]. It is this reactive
nature that is thought to be responsible for their potent and wide-
ranging properties [63,64]. Proteomic approaches have identified
the conjugation of 15d-PGJ2 with many protein targets including
multiple components of mitochondria, the cytoskeleton and also
transcriptional networks such as NF-k B [30–38]. Importantly, B/
M treatment of AML cell lines and primary AMLs recapitulated
some of the known anti-neoplastic activities of 15d-PGJ2. However
these actions were not uniform across all the cell types tested.
Similarly, we observed differential apoptotic and differentiation
responses to B/M in both AML cell lines and primary AML cells.
These variations may reflect the molecular heterogeneity of AML
and the consequent contextual actions of 15d-PGJ2.
In contrast, 15d-PGJ2 also generated ROS in all AML cell lines
and primary AML cells tested. It may therefore be that B/M
treatment induces a cycle of direct and secondary 15d-PGJ2-
mediated ROS generation thereby perpetuating a cycle of
glutathione depletion and oxidative stress. The importance of
ROS as well as 15d-PGJ2 in mediating the anti-leukaemic activity of
B/M is highlighted by our recent NMR based metabolomics study
of B/M treated AML cell lines [18]. It has been shown that ROS
mediates the direct chemical conversion of a-ketoglutarate to
succinate [65,66,67]. Notably, our metabolomics study identified
Figure 7. Downstream consequences of elevating 15d-PGJ2 levels. (A) Elevating 15d-PGJ2 levels results in lowering of reduced-glutathione
(GSH). HL60 cells were treated for 48 hours and mg GSH per mg of protein measured. Data shown is from 4 experiments and the mean is indicated by
a black bar. (B) PPARc transcriptional activity was measured after 14 hours treatment of PPRE-luciferase reporter plasmid and pRenilla luciferase
transfected HL60 cells with either MPA, BEZ, the combination (B/M) or 5 mM 15d-PGJ2 (PGJ2). Data shown is luciferase activity compared to control
untreated cells for N=5 experiments. Mean is indicated by black bar. (C&D)I kB levels were determined by western blotting of cells treated for
14 hrs. Levels were normalised for loading by b-actin westerns. (C) Representative western blot results for HL60, KG1a and a primary AML. (D) Graph
represents mean6sem of densitometry performed on a minimum of N=3 experiments for each cell line. All individual datapoints are shown in Figure
S7. Statistics: * p,0.05.
doi:10.1371/journal.pone.0008147.g007
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depletion of a-ketoglutarate and the accumulation of succinate [18].
Thiseffect wasrecapitulated in cell extracts by the application of the
ROShydrogen peroxide.Thereforethe antileukaemic actions of B/
M against AML are complex and most likely mediated by separate
and overlapping actions of both 15d-PGJ2 and ROS.
Although our studies have focused upon the accumulation of
PGD2 and 15d-PGJ2 in B/M treated AML cells, it should not be
ignored that part of the activity of MPA against AML cells may
also be mediated by the diminution of 11b-PGF2a (Figure S8) and
future studies should address this possibility. Furthermore, since
the anti-neoplastic activities of 15d-PGJ2 have been demonstrated
in multiple tumour models [21–29], the potential of B/M based
therapy may also extend beyond AML into other 15d-PGJ2
sensitive tumours. Our observations that B/M has greater efficacy
against CLL, BL and now AML cells than either BEZ or MPA
alone would appear to support this contention. However, it is
important to note that although we have demonstrated that CLL
cells express AKR1C3 we were unable to demonstrate AKR1C3
PGD2-11-ketoreductase activity in these cells [20]. These
observations indicate that the substrate promiscuity of AKR1C3
is of real biological importance and has implications for its
functions in different cell contexts. Hence, further studies are
required to determine how B/M and particularly MPA or other
AKR1C3 inhibitors exert anti tumour activities in different
tumour settings.
In summary our findings support the investigation of B/M as
novel therapy in elderly and relapsed AML. We have instigated
such a trial, the results of which will be published in the near
future. Given the low direct and supportive care costs of these
agents, and their activity against multiple tumour types this study
identifies an affordable potential anti-cancer therapy in developing
countries where fiscal and other restraints limit the availability of
conventional chemotherapy.
Materials and Methods
Reagents
Bezafibrate (0.5 M in DMSO), MPA (5 mM in ethanol), ATRA
(1 mM in DMSO), and 1a, 25(OH)2 vitamin D3 (1 mM in
Figure 8. Physiological levels of ATRA and Vitamin D3 potentiate the actions of BEZ and MPA. (A) HL60 cells were treated for 7 days with
solvent control, B/M alone and B/M combined with either 1 nM ATRA, 1 nM 1a,25(OH)2 vitamin D3 (D3) or both. A representative histogram of CD11b
flow cytometry is shown in the left panel and results from N=4 experiments in the middle panel. Mean is indicated by the black bar. (B) Cell
morphology was analysed by Jenner-Giemsa staining of cytospins. Differentiated neutrophils are identified by classical poly-lobed nuclei (arrows) and
apoptotic cells highlighted by asterix. Statistics: *p,0.001. (C) Primary AML cells taken from a karyotypically normal non-APL AML were treated with
solvent CONT, B/M61nmATRA/1nM D3. Differentiation was determined by CD11b staining and flow cytometry and by morphological analysis of
Jenner-Giemsa stained cytospins after 18 days of treatment. (D) ROS generation was measured as described above in primary AML cells treated with
cont, B/M61nmATRA/1nM D3 for 48 hours.
doi:10.1371/journal.pone.0008147.g008
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12,14PGJ2 (Affiniti, UK)
were dissolved in DMSO to yield 20 mM stocks and stored at
220uC.
In Vitro Recombinant AKR1C3 Activity Assay
Recombinant N-terminal His-tagged recombinant AKR1C3
was produced as previously described [68]. Enzyme reactions
(1 ml-volumes) contained 15 mg recombinant AKR1C3, 4 mM
phenanthrenequinone (Sigma, UK), 150 mM NADPH (Sigma)
and 0–100 mM MPA in 50 mM potassium phosphate buffer
(pH 6.5) at 35uC and measured as the rate of change of pyridine
nucleotide absorbance at 340 nm.
Primary Cells, Cell Lines and Treatments
HL-60, NB4, U937, K562 and KG1a myeloid cell lines were
maintained in RPMI 1640 medium supplemented with 10%
(v/v) heat-inactivated fetal bovine serum (FBS) and penicillin/
streptomycin (Gibco, Invitrogen Ltd, UK). Unless specified
otherwise, 1610
6 cells in 4 mls were treated with solvent control,
5 mM MPA, 0.5 mM BEZ or the combination B/M. 1 nM
ATRA+1 nM Vitamin 1,25(OH)2 vitamin D3 (D3) (Sigma, UK),
10 mM PGD2 or 5–10 mM 15d-PGJ2 were added where specified.
Primary AML mononuclear cell preparations were prepared using
Ficoll Paque-Plus (Pharmacia Biotech, UK) from presentation
aspirates and peripheral blood samples provided after informed
consent and ethical committee approval from ongoing phase I/II
trials currently undertaken within the University of Birmingham
Hospitals NHS Trust and from the MRC AML 15 phase III trial.
The resultant AML blast preparations were cultured at
1610
6 cells/ml in RPMI 1640 supplemented with 1% (v/v)
ITS
+ (VWR, UK), IL3 (1 ng/ml) and SCF (10 ng/ml) (both R&D
Systems, UK). For treatments, primary AML cells were set at
1610
6 cells/ml with either solvent control, 5 mM MPA, 0.5 mM
(500 mM) BEZ or B/M, 61 nM ATRA+D3. Viability was
determined by manual cell counts and cytospin preparations
made for analysis of morphology. Normal donor mobilised
peripheral blood samples were provided under ethical approval
and informed consent by the National Blood Service, Stem
Cell Laboratories, Birmingham, UK, and treated as for primary
AML cells.
3H-PGD2 Turnover Analysis by Thin Layer
Chromatography
PGD2 turnover in intact cells was determined similarly to that
described previously [28]. Briefly, 2610
6 KG1a cells were
incubated with 0.2 mCi/1.3pmoles
3H-PGD2 (Amersham Biosci-
ences) in warm PBS for 9 hours. Prostaglandin extracts were
prepared from supernatants and separated on silica gel/TLC
plates before reading on a Bioscan plate reader. Prostanoids were
identified by their co-migration with known standards (Biomol
International L.P., UK) visualized by placing in a sealed tank filled
with iodine vapor for approximately 5 minutes.
Lipid Peroxidation Assay
2610
6 cells at 2.5610
5/ml were treated at 37uC for 2 hours
with the addition of 10 mM cis-parinaric acid (a naturally
fluorescent lipid) for the last 30 mins. Cells were harvested and
lipids extracted in the dark for 1 hour with isopropanol + 0.05%
butylated hydroxytoluene. Fluorescence readings were taken at
320 nmexcitation/415 nmemission. Background fluorescence of lipids
extracted from unlabelled control cells was subtracted from all
values and data presented as % fluorescence units (FU) compared
to solvent control cells.
Assessment of Accumulation of ROS
Cells were treated for 14 hours at 37uC and 10 mM carboxy-
H2DCFDA (Molecular Probes, Invitrogen, UK) added to cells for
the final 45 mins. Following incubation, cells were washed with
PBS and analysed by flow cytometry (Becton Dickinson FACS
Calibur and Becton Dickinson Cell Quest software).
Prostaglandin ELISAs
Prostaglandin D2-MOX EIA kit (Cayman Chemicals, USA) and
15D
12,14Prostaglandin J2 Enzyme Immunoassay Kit (Assay De-
signs, Inc., USA) were used to determine prostaglandin levels.
5610
6 cells were treated for 2 hours. Following treatment, cells
were harvested with 1 ml culture media and homogenised using a
Precellys 24 ceramic bead based homogenisation system. Prosta-
glandinswere extracted usingC18reverse phaseextractioncolumns
(Chromabond, Fisher, UK) and levels determined by ELISA.
Measurement of GSH Levels
3610
6 cells were treated at 2.5610
5/ml, cell pellets prepared
and GSH levels determined as described previously [69].
PPRE Reporter Assays
Briefly, 2610
6 HL-60 cells were transfected with 2.5 mg
p4xACO-Luciferase (kind gift from Prof Bert Vogelstein, John
Hopkins, USA) and 0.5 mg pRenilla-luciferase (Promega, UK)
using Solution V and file T19 on the AMAXA Nucleofector I
system. Transfected cells were allowed to recover for 14 hrs and
then treated for 24 hrs. Cells were harvested and luciferase
measured using the Dual-GloH Luciferase Assay Kit (Promega,
UK) according to manufacturer’s instructions.
Western Blot Analyses
Cells treated with drugs for 14 hrs were lysed in RIPA buffer
and 30 mg proteins separated by SDS-PAGE. Proteins were
transferred to Immobilon-P membrane (Millipore Corp, Bedford,
MA, USA) and probed with 1/1000 dilution of anti-IkB (Santa
Cruz, USA). Detection was by anti-rabbit-horse radish peroxidise
(HRP) diluted 1/1000 and ECL using Supersignal West Pico
Chemiluminescent substrate (Pierce, USA). Loading controls used
anti b-actin antibody (Sigma UK) diluted 1/25000 and anti-
mouse-HRP secondary at 1/25000. Densitometry was performed
using ImageJ software (http://rsb.info.nih.gov/ij/) and IkB
protein expression normalised to b-actin.
Measurement of Relative Number of Viable Cells
Myeloid cell lines were treated for 7 days with refeeding every 2
days. Numbers of viable cells in triplicate 100 ml aliquots of
cultures were determined using CellTiter-BlueH reagent (CellTi-
ter-BlueH Cell Viability Assay, Promega, UK). Readings were
adjusted for feeding schedules over the course of treatment.
Assessment of Cell Differentiation
Myeloid cell lines were treated for 7 days with refeeding and
retreating every 2 days. Analysis of differentiation antigen
expression was by flow cytometry (Becton Dickinson FACS
Calibur and Becton Dickinson Cell Quest software) using FITC
CD71 and PE-CD11b (Becton Dickinson) conjugated antibodies
for HL60, U937, NB4 and KG1a cells. FITC-Glycophorin-A was
used to determine erythroid differentiation of K562 (Serotec, UK).
Assessment of Apoptosis by Annexin-V
Phosphotidylserine cell surface expression was assessed using
Annexin-V FITC kit (Becton Dickinson, UK). Analyses were
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Calibur utilising Cell Quest Pro software (Becton Dickinson, UK).
Jenner Giemsa Staining of Slides
Cytospins were prepared from 75–100 ml of culture. Slides were
air-dried, methanol fixed and stained; first with Jenner staining
solution (VWR, UK) diluted 1/3 in 1 mM sodium phosphate
buffer pH 5.6 (5 mins) and second with Giemsa stain (VWR, UK)
diluted 1/20 in 1 mM sodium phosphate buffer pH 5.6 (10 mins).
Slides were dried and then mounted onto coverslips using DePex
(VWR, UK).
Statistics
Data were analysed using SPSS v15 and the non-parametric
Mann-Whitney U test. Unless stated in the legend, the statistics
shown in figures are all compared to control cultures.
Supporting Information
Figure S1 Cell viability is reduced in Myeloid cell lines treated
with BEZ, MPA or B/M. Cell viability as % of solvent treated
controls was determined in 5 myeloid cell lines by Alamar Blue
assay following treatment with either solvent control, 0.5 mM
BEZ, 5 uM MPA or the combination (B/M) for 7 days. Cell
viability was calculated for treatments relative to solvent treated
controls after readings had been adjusted for feeding regimens
over the 7 days of treatment. Mean is indicated by the black bars.
Statistics * p,0.01.
Found at: doi:10.1371/journal.pone.0008147.s001 (0.12 MB PPT)
Figure S2 Effect of BEZ, MPA and B/M on myeloid cell lines.
(A) Differentiation was measured by flow-cytometry using the
myeloid differentiation antigen CD11b for HL60, NB4, U937,
KG1a cells and the erythroid antigen Glycophorin-A for
differentiation of K562. Scatter plots show data from a minimum
of N=3 experiments. Mean is indicated by black bar. (B) % Sub-
G1 events were measured by flow cytometry cell cycle analysis of
propidium iodide stained cells following 7 days treatment. Scatter
plot shows data from a minimum of N=3 experiments. Mean is
indicated by black bar.
Found at: doi:10.1371/journal.pone.0008147.s002 (0.21 MB PPT)
Figure S3 PGD2 synthesis, metabolism and non-enzymatic
conversions towards 15dD
12,14PGJ2.A d a p t e df r o mG a oe ta l ,
2003 (JBC 278: 28479–89). PGD2 is highly unstable and rapidly
undergoes non-enzymatic conversions to form 15dD
12,14PGJ2
in the absence of AKR1C3. Solid arrows and dotted arrows
indicate enzyme mediated and non-enzymatic conversions
respectively.
Found at: doi:10.1371/journal.pone.0008147.s003 (0.09 MB PPT)
Figure S4 ROS induction in myeloid cell lines and primary
AMLs. Reactive oxygen species (ROS) induction was determined
by staining with carboxy-H2 DCFDA and flow cytometry in
HL60, KG1a and primary AML samples after 48 hours treatment
with CONT, B/M or 10 mM 15d-PGJ2. Data shown is N=4 for
HL60 and KG1a and N=3 primary AMLs. Mean is indicated by
black bar. Statistics * p,0.01
Found at: doi:10.1371/journal.pone.0008147.s004 (0.06 MB PPT)
Figure S5 1H-1H 2D correlation spectroscopy (COSY) NMR
spectrum of KG1a cells extracts. Expanded region (2.6–4.8 ppm)
of 1H-1H 2D COSY 45 (COrrelation SpectroscopY) NMR
spectrum acquired on dried polar extracts of KG1a cells (solvent
control treatment) redissolved in 99.9% D2O (GOSS Scientific
Instruments Ltd, Essex UK). 2D COSY experiments were carried
out using 800 MHz Varian spectrometer equipped with a
cryogenically cooled probe using a gradient-selected coherence
transfer pathway (gCOSY45) (Hurd, John & Plant, 1991, J Mag
Reson, 93: 666) with 16 transients of 8192 complex data points,
256 increments, and a spectral width of 8 kHz in both dimensions.
The highlighted peaks (red lines) are due to oxidized (GSSG) and
reduced (GSH) glutathione.
Found at: doi:10.1371/journal.pone.0008147.s005 (0.42 MB PPT)
Figure S6 1H 1D NMR spectrum of KG1a cells extracts. Cells
were treated for 24 hours and polar extracts analysed by NMR.
Extraction of metabolites from cells pellets was performed using a
modified Bligh-Dyer procedure. Dried polar extracts were
redissolved in 90% H2O/10% D2O (GOSS Scientific Instruments
Ltd, Essex UK) with phosphate buffer (100 mM, pH 7),
containing 0.5 mM TMSP. A 500 MHz Bruker spectrometer
equipped with a cryogenically cooled probe was used for 1D 1H
data acquisition. The water resonance was suppressed using
excitation sculpting (Hwang & Shaka, 1998, J Magn Reson, 135:
280). 1D spectra were acquired using a 60u pulse, a 5 kHz spectral
width, a relaxation delay of 3 s with 128 transients. 3 different
sections (2.15–2.22, 2.50–2.62, and 2.95–3.02 ppm) of the 1H 1D
NMR spectrum of KG1a cell extracts containing glutathione
peaks. A minimum of 12 replicates for each treatment (black,
solvent control; red, MPA, green BEZ, blue B/M) are shown. The
insert depicts the average spectrum of 12 replicates expanded
between 2.15–2.22 ppm.
Found at: doi:10.1371/journal.pone.0008147.s006 (0.22 MB PPT)
Figure S7 I-kappa B levels are reduced in some myeloid cell
lines following treatment with B/M. IkB levels were determined by
western blotting of cells treated with either solvent control,
0.5 mM BEZ, 5 mM MPA or the combination for 14 hrs. Levels
were normalised for loading by b-actin westerns and densitometry.
Scatter plots show all datapoints for a minimum of N=3
experiments for each cell lines. Means are indicated by black
bars. Statistics *p,0.05
Found at: doi:10.1371/journal.pone.0008147.s007 (0.11 MB PPT)
Figure S8 Model of B/M action against AML cells. ROS
directly generated by BEZ and indirectly by subsequently
generated 15-deoxy-D
12,14PGJ2, enhances PGD2 production via
the lipid peroxidation isoprostane pathway. Inhibition of
AKR1C3 by MPA results in diversion of PGD2 towards the J
series prostaglandins culminating in the pleiotropic anti neoplastic
actions of 15-deoxy-D
12,14PGJ2 including further generation of
ROS and activation of lipid peroxidation.
Found at: doi:10.1371/journal.pone.0008147.s008 (0.10 MB PPT)
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